Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
91% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. PGNX: No Debt )
PGNX' s 10-Year Cash to Debt Range
Min: 3   Max: No Debt
Current: No Debt

Equity to Asset 0.69
PGNX's Equity to Asset is ranked higher than
74% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PGNX: 0.69 )
PGNX' s 10-Year Equity to Asset Range
Min: -0.24   Max: 0.97
Current: 0.69

-0.24
0.97
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
71% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
PGNX' s 10-Year Interest Coverage Range
Min: 2   Max: 9999.99
Current: No Debt

2
9999.99
F-Score: 2
Z-Score: -2.14
M-Score: -1.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -546.68
PGNX's Operating margin (%) is ranked higher than
57% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. PGNX: -546.68 )
PGNX' s 10-Year Operating margin (%) Range
Min: -1033.33   Max: 35.35
Current: -546.68

-1033.33
35.35
Net-margin (%) -541.49
PGNX's Net-margin (%) is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. PGNX: -541.49 )
PGNX' s 10-Year Net-margin (%) Range
Min: -1016.67   Max: 33.31
Current: -541.49

-1016.67
33.31
ROE (%) -53.90
PGNX's ROE (%) is ranked higher than
61% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. PGNX: -53.90 )
PGNX' s 10-Year ROE (%) Range
Min: -135.89   Max: 22.17
Current: -53.9

-135.89
22.17
ROA (%) -37.17
PGNX's ROA (%) is ranked higher than
64% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. PGNX: -37.17 )
PGNX' s 10-Year ROA (%) Range
Min: -358.82   Max: 20.82
Current: -37.17

-358.82
20.82
ROC (Joel Greenblatt) (%) -1781.19
PGNX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. PGNX: -1781.19 )
PGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1781.19   Max: 773.29
Current: -1781.19

-1781.19
773.29
Revenue Growth (%) -16.40
PGNX's Revenue Growth (%) is ranked higher than
65% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. PGNX: -16.40 )
PGNX' s 10-Year Revenue Growth (%) Range
Min: -55.7   Max: 73.2
Current: -16.4

-55.7
73.2
EBITDA Growth (%) -28.60
PGNX's EBITDA Growth (%) is ranked higher than
59% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. PGNX: -28.60 )
PGNX' s 10-Year EBITDA Growth (%) Range
Min: -28.6   Max: 51.4
Current: -28.6

-28.6
51.4
EPS Growth (%) -29.20
PGNX's EPS Growth (%) is ranked higher than
62% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. PGNX: -29.20 )
PGNX' s 10-Year EPS Growth (%) Range
Min: -73.5   Max: 221.4
Current: -29.2

-73.5
221.4
» PGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PGNX Guru Trades in Q1 2013

Paul Tudor Jones 2,342,388 sh (unchged)
Murray Stahl 65,200 sh (unchged)
Jim Simons Sold Out
» More
Q2 2013

PGNX Guru Trades in Q2 2013

Jim Simons 103,089 sh (New)
Murray Stahl 67,200 sh (+3.07%)
Paul Tudor Jones 2,342,388 sh (unchged)
» More
Q3 2013

PGNX Guru Trades in Q3 2013

Steven Cohen 32,206 sh (New)
Louis Moore Bacon 50,000 sh (New)
Jim Simons 280,100 sh (+171.71%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (unchged)
» More
Q4 2013

PGNX Guru Trades in Q4 2013

Louis Moore Bacon 95,000 sh (+90%)
Paul Tudor Jones 2,342,795 sh (+0.02%)
Murray Stahl 67,200 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PGNX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
PGNX's P/B is ranked higher than
77% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PGNX: 2.70 )
PGNX' s 10-Year P/B Range
Min: 1.08   Max: 16.48
Current: 2.7

1.08
16.48
P/S 24.80
PGNX's P/S is ranked lower than
66% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. PGNX: 24.80 )
PGNX' s 10-Year P/S Range
Min: 1.92   Max: 62.55
Current: 24.8

1.92
62.55
EV-to-EBIT 12.30
PGNX's EV-to-EBIT is ranked higher than
75% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. PGNX: 12.30 )
PGNX' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 72
Current: 12.3

9.8
72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.00
PGNX's Price/Net Cash is ranked higher than
65% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. PGNX: 7.00 )
PGNX' s 10-Year Price/Net Cash Range
Min: 1.64   Max: 13.1
Current: 7

1.64
13.1
Price/Net Current Asset Value 6.60
PGNX's Price/Net Current Asset Value is ranked higher than
67% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. PGNX: 6.60 )
PGNX' s 10-Year Price/Net Current Asset Value Range
Min: 1.54   Max: 12.62
Current: 6.6

1.54
12.62
Price/Tangible Book 5.30
PGNX's Price/Tangible Book is ranked higher than
60% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PGNX: 5.30 )
PGNX' s 10-Year Price/Tangible Book Range
Min: 1.32   Max: 9.28
Current: 5.3

1.32
9.28
Price/Median PS Value 2.30
PGNX's Price/Median PS Value is ranked lower than
64% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PGNX: 2.30 )
PGNX' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 4.6
Current: 2.3

0.24
4.6
Earnings Yield (Greenblatt) 8.10
PGNX's Earnings Yield (Greenblatt) is ranked higher than
76% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PGNX: 8.10 )
PGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.2
Current: 8.1

1.4
10.2
Forward Rate of Return (Yacktman) -23.94
PGNX's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. PGNX: -23.94 )
PGNX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.6   Max: -9
Current: -23.94

-19.6
-9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PGP.Germany
Progenics Pharmaceuticals, Inc. is engaged in the research and development of biotechnology product candidates in the areas of oncology, virology, supportive care, and gastroenterology. The company offers RELISTOR, a subcutaneous injection for the treatment of opioid induced constipation in patients with advanced illnesses, such as cancer. It is also developing RELISTOR, a subcutaneous injection for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. The company's principal product candidate under development is PSMA ADC, which is in Phase I trial in men with advanced prostate cancer. PSMA ADC is an antibody-drug conjugate that targets prostate specific membrane antigen, a protein found on the surface of prostate cancer tumor cells, as well as on the neovasculature of various other types of solid tumors. In addition, the company is developing PI3K, a pre-clinical stage novel multiplex phosphoinositide 3-kinase inhibitor for blocking signaling pathways that are critical in the growth of aggressive cancers. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR around the globe other than Japan.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide